Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial
EP Sloan, M Koenigsberg, D Gens, M Cipolle, J Runge… - Jama, 1999 - jamanetwork.com
ContextSevere, uncompensated, traumatic hemorrhagic shock causes significant morbidity
and mortality, but resuscitation with an oxygen-carrying fluid might improve patient
outcomes. ObjectiveTo determine if the infusion of up to 1000 mL of diaspirin cross-linked
hemoglobin (DCLHb) during the initial hospital resuscitation could reduce 28-day mortality
in traumatic hemorrhagic shock patients. Design and SettingMulticenter, randomized,
controlled, single-blinded efficacy trial conducted between February 1997 and January 1998 …
and mortality, but resuscitation with an oxygen-carrying fluid might improve patient
outcomes. ObjectiveTo determine if the infusion of up to 1000 mL of diaspirin cross-linked
hemoglobin (DCLHb) during the initial hospital resuscitation could reduce 28-day mortality
in traumatic hemorrhagic shock patients. Design and SettingMulticenter, randomized,
controlled, single-blinded efficacy trial conducted between February 1997 and January 1998 …